Uroplasty, a medical device company that develops, manufactures and markets proprietary products for the treatment of voiding dysfunctions, has received US Patent No 7,729,772 for its neuromodulation system.

Uroplasty said that the patent covers a method for using an implantable neuromodulation system in the treatment of urinary incontinence by neuromodulation or stimulation of the tibial nerve. The system includes a portable, external transmitter and a receiver implanted subcutaneously in the leg or ankle near the tibial nerve.

David Kaysen, president and CEO, said: “This newly-issued patent broadens our portfolio of neuromodulation patents, which includes patents covering our Urgent PC System, a product we have commercialized in the US since 2006 for the treatment of urinary urgency, urinary frequency, and urinary urge incontinence.

“While we have not begun work on nor have any current plans for product development related to this implantable neuromodulation patent, this newly-issued patent could offer an opportunity to broaden our product offering.”

Headquartered in Minnetonka, Minnesota, Uroplasty, with wholly-owned subsidiaries in The Netherlands and the UK, is a medical device company that focuses in the continued commercialisation of Urgent PC System.

Urgent PC System is the FDA-approved minimally invasive neuromodulation device designed for office-based treatment of urinary urgency, urinary frequency and urge incontinence – symptoms often associated with overactive bladder.

The company also offers Macroplastique, an injectable bulking agent for the minimally invasive treatment of adult female stress urinary incontinence primarily due to intrinsic sphincter deficiency.